Published: July 6, 2017

Introduction {#sec1}
============

The adult liver is a highly regenerative organ that responds to injury with extensive cell proliferation. Although the mature epithelial cells (hepatocytes and cholangiocytes) can divide extensively, it has long been thought that the liver may harbor facultative stem cells which are called upon in certain chronic injury situations ([@bib9], [@bib29]). In the intestine, multilineage stem cells are found at the bottom of the crypts and express the R-spondin receptor LGR5 ([@bib23]). The adult liver of both mice and humans also harbors cells that can give rise to Lgr5^+^ hepatic organoids comparable with those generated from the intestine ([@bib20], [@bib21]). In the intestine, Lgr5^+^ cells are observable during normal homeostasis and have been shown to be bona fide stem cells ([@bib2], [@bib3]). Although adult liver does not contain Lgr5^+^ cells during normal homeostasis, such cells can emerge under conditions of injury and can give rise to hepatic organoids *in vitro* ([@bib20]). Cultured hepatic organoids display extensive self-renewal and express hepatocyte-like properties after *in vitro* differentiation. They also can produce limited *in vivo* engraftment after transplantation, but the efficiency of this process is significantly lower than with true hepatocytes.

We recently showed that the precursor to Lgr5^+^ organoid-forming cells resides in the ductal compartments of the liver and pancreas in mice ([@bib8]). It is currently unclear whether these highly clonogenic ductal cells are bipotential, i.e., can clonally produce both cholangiocytes and hepatocytes, in the adult liver ([@bib11], [@bib32], [@bib35], [@bib36], [@bib38]). It is also unclear whether this population contributes significantly to liver injury repair *in vivo*. Multiple genetic lineage tracing studies performed in mice argue against a contribution of ductal progenitors to the functional hepatocyte pool even with chronic injury ([@bib18]). Nonetheless, experiments performed in other species, most notably the rat, suggest that a bipotential liver stem cell does exist and that it resides within the cholangiocyte compartment ([@bib12], [@bib15], [@bib31]). Our previous work showed that the clonogenic (organoid-forming) population in the adult mouse liver is heterogeneous at the single-cell level ([@bib7], [@bib8]) and that only approximately 1 out of 20 fluorescence-activated cell sorting (FACS)-purified biliary duct cells are clonogenic. We therefore wished to further refine the precursor population for Lgr5^+^ hepatic organoids and determine some of their key properties, such as their transcriptome. Here we demonstrate that adult mouse biliary duct epithelium is indeed functionally and transcriptionally heterogeneous. Differential expression of the cell surface marker ST14 was used to purify and study the organoid-forming population in the adult mouse liver, defining two distinct subtypes of adult cholangiocytes.

Results {#sec2}
=======

Characterization of Duct Cell Heterogeneity {#sec2.1}
-------------------------------------------

Biliary cells positive for the cell surface marker MIC1-1C3 have been previously shown to contain the precursors for Lgr5^+^ hepatic organoids ([@bib8]). To further enrich clonogenic cells within this fraction, we searched for cell surface markers with heterogeneous expression in this population. Analysis of the DNA microarray data of the MIC1-1C3^+^/CD133^+^/CD26^−^ clonogenic adult liver population ([@bib6], [@bib7]) revealed several candidate markers including CD24, ANXA13, SLC34A2, COLLECTRIN, and ST14 (suppression of tumorigenicity 14). All of these were tested by FACS to determine whether they could further subdivide the clonogenic cholangiocyte population. Among the markers tested, ST14 gave the cleanest separation ([Figures 1](#fig1){ref-type="fig"}, [S1](#mmc1){ref-type="supplementary-material"}E--S1G, and S1I); approximately 20.9% of cells were ST14^hi^ and 65.6% ST14^lo^. Immunofluorescent labeling also showed that ST14 and the cholangiocyte marker EpCAM (epithelial cellular adhesion molecule) had partially overlapping distributions: EpCAM-expressing cells can be either ST14-positive or -negative ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Moreover, ST14 protein heterogeneity in human duct cells could also be found ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 1FACS Strategy for Adult Duct CellsThe sequence of the sorting work flow is shown from left to right in (A) to (E). Mouse liver non-parenchymal (NPC) cells were labeled with MIC1-1C3, ST14, CD26, CD31, CD45, and CD11b.(A and B) Cells were sequentially gated based on cell size (forward scatter \[FSC\] versus side scatter \[SSC\]) (A) and singlets (FSC versus trigger pulse width) (B).(C) Dead cells and debris were excluded by detection of propidium iodide (PI) positivity. Concurrently a combination of CD45, CD31, and CD11b antibodies was used for depleting blood, endothelium, and Kupffer cells.(D) CD26 (DPPIV) was used for hepatocyte staining.(E) MIC1-1C3^+^ cells can be subdivided into two populations: ST14 high (ST14^hi^M^+^) and ST14 low (ST14^lo^M^+^).(F) Size and scatter properties of fully gated ST14^hi^M^+^ cells.n = 10 independent mice. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Robust Single-Cell-Derived Organoid-Forming Efficiency {#sec2.2}
------------------------------------------------------

To investigate the expansion capability of these different cholangiocyte populations, we collected MIC1-1C3^+^ cells expressing high levels of ST14 (ST14^hi^M^+^) and MIC1-1C3^+^ cells expressing low levels of ST14 (ST14^lo^M^+^) by FACS. Their clonogenic potential was then tested in a modified hepatic organoid-forming assay ([@bib8], [@bib20]). Single ST14^hi^ and ST14^lo^ cells were deposited by FACS into a 96-well plate prefilled organoid culture medium ([Figure 2](#fig2){ref-type="fig"}A). At day 14 of culture, the ST14^hi^ cells had formed larger organoids than ST14^lo^ duct cells ([Figures 2](#fig2){ref-type="fig"}B and 2C). They also had a higher a priori organoid-forming efficiency (14 ± 4.8 organoids per 100 input cells, mean 1/7, n = 16) compared with ST14^lo^ cells (5.4 ± 2.5 organoids per 100 input cells, mean 1/22, n = 8) ([Figures 2](#fig2){ref-type="fig"}D and 2E). Large organoids (\>200 μm diameter) were produced from only the ST14^hi^M^+^ population ([Figure 2](#fig2){ref-type="fig"}F). The capacity for serial expansion was tested by passaging established organoids from the initial 96-well plates to 24-well plates. Organoids established from ST14^hi^ cells displayed higher proliferation rates and could be passaged more efficiently than the small organoids from ST14^lo^ cells ([Figures 2](#fig2){ref-type="fig"}G and 2H): Organoids initiated by ST14^hi^ cells could be passaged more than three times while those from ST14^lo^ cells could not be passaged more than twice ([Figures 2](#fig2){ref-type="fig"}C, 2G, and 2H). To determine whether ST14 was expressed in organoids *in vitro*, we performed FACS analysis. More than 65% of cells in the ST14^hi^ derived organoids were ST14^+^ ([Figure 2](#fig2){ref-type="fig"}I, n = 4). Moreover, we found *Lgr5* mRNA expressed only in ST14^hi^ but not ST14^lo^ cells from ST14^hi^ cell-derived organoids ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Furthermore, ST14^hi^ cell-derived organoids displayed low levels of expression of the mature hepatocyte marker Fah after differentiation *in vitro* ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Taken together, these results indicated that ST14^hi^ ductal cells had a higher colony-forming ability, grew faster, and could be serially passaged with higher efficiency than their ST14^hi^ counterparts. We therefore designated the ST14^hi^M^+^ population as clonogenic organoid-forming biliary cells.Figure 2Clonogenicity of Biliary Duct Subsets(A) Individual FACS-sorted ST14^hi^M^+^CD26^−^CD45/31/11b^−^ and ST14^lo^M^+^CD26^−^ CD45/31/11b^−^ cells were directly deposited into individual cells of a 96-well plate.(B) Representative morphology of organoids generated by M^+^ST14^lo^ and M^+^ST14^hi^ cells. Culture day 14. Scale bars, 100 μm.(C) Long-term expansion of M^+^ST14^hi^ population colonies. P, number of passages. Scale bar, 100 μm.(D) Colony-forming efficiency of single cells. The M^+^ST14^lo^ population had an efficiency of ∼5.4% and M^+^ST14^hi^ an efficiency of13.4%. p = 0.0001. Statistical analysis by unpaired t test. CFU, colony-forming unit (n = 8 plates from four independent mice for ST14^lo^, n = 16 plates from eight independent mice for ST14^hi^).(E) Poisson distribution of M^+^ST14^lo^ versus M^+^ST14^hi^ organoid-forming efficiency from (D). The M^+^ST14^lo^ population gave rise to an average of five colonies per 96-well plate while M^+^ST14^hi^ gave rise to an average of 13. The distribution was clearly bimodal.(F) Size distribution of organoids derived from single cells. Statistical analysis by t test (n = 3 independent experiments). ^∗^p \< 0.01.(G) Representative images of three different single-cell-derived M^+^ST14^hi^ clones during serial passage. Scale bars, 100 μm (left panels) and 2 mm (middle and right panels).(H) Efficiency of serial passage for the different populations. None of the organoids derived from M^+^ST14^lo^ cells could be passaged more than three times. Statistical analysis by unpaired t test. Independent organoids for ST14^hi^ in P2, n = 7; ST14^lo^ in P3, n = 3; ST14^hi^ and ST14^lo^ in P3, n = 3.(I) Flow-cytometry analysis of ST14 expression in the M^+^ST14^hi^ (n = 4 independent experiments) and ST14^lo^ (n = 3 independent experiments) derived organoids after *in vitro* expansion (unpaired t test, mean ± SD, p = 0.0117).See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

ST14^hi^ Cells Survive Longer Than Other Duct Cells Post Mortem {#sec2.3}
---------------------------------------------------------------

We previously reported that mouse liver harbors transplantable hepatocytes for up to 24 hr after death ([@bib10]). We therefore wished to determine the postmortem survival of organoid-forming, clonogenic biliary cells. Mice were euthanized and kept at room temperature until later cell isolation by liver perfusion. Interestingly, large numbers of viable (propidium iodide-negative) cholangiocytes could still be isolated by FACS 24 hr after death. This duct population retained clonogenic activity and was able to form organoids capable of serial passage *in vitro* ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Moreover, the ST14^hi^ subpopulation increased to ∼45% of M^+^ duct cells compared with only 21% in the normal liver ([Figure S2](#mmc1){ref-type="supplementary-material"}B). These data indicate that adult liver clonogenic cholangiocytes are resistant to prolonged warm ischemia.

ST14^hi^ Cells Are Present in Injured Liver {#sec2.4}
-------------------------------------------

To assess the expression of ST14 during injury, we used the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet and carbon tetrachloride (CCl~4~) to induce liver damage as previously reported ([@bib20]). Importantly, the ST14^hi^ percentage among MIC1-1C3^+^ duct cells ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2F) remained stable during injury. In addition, the organoid-forming frequency of ST14^hi^ cells from the injured liver was similar to that in normal liver ([Figure S2](#mmc1){ref-type="supplementary-material"}G). These findings suggest that acute liver injury did not result in a selective expansion or loss of the clonogenic cholangiocyte population.

Transcriptomes of Adult Biliary Duct Subpopulations {#sec2.5}
---------------------------------------------------

To compare the ST14^hi^M^+^ and ST14^lo^M^+^ populations at the transcriptional level, we extracted RNA from freshly FACS-sorted cells for sequencing. Multiple replicates (four ST14^hi^ and four ST14^lo^) from independent cell isolations were analyzed. There were no significant differences between ST14^hi^ and ST14^lo^ populations in the expression of prototypical cholangiocyte cell markers such as *Sox9*, *Epcam*, and *Krt19* ([Figure 3](#fig3){ref-type="fig"}B and [Table S2](#mmc1){ref-type="supplementary-material"}), confirming the biliary duct nature of both populations. However, a sizable list of genes was gene was differentially expressed between the two populations. A total of 658 genes were upregulated and 241 genes downregulated in the ST14^hi^ population using a false discovery rate (FDR) of \<0.1 as the cutoff ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}); 308 genes were upregulated in the ST14^hi^ population with an FDR of \<0.05 and 185 genes were upregulated with an FDR of \<0.01. Interestingly, ST14 itself was not differentially expressed at the mRNA level ([Table S1](#mmc1){ref-type="supplementary-material"}), suggesting that the heterogeneity observable at the protein level must be due to post-transcriptional mechanisms ([@bib5], [@bib28], [@bib40]).Figure 3Transcriptome Analyses of M^+^ST14^hi^ and M^+^ST14^lo^ Duct Cells(A) Kendal\'s tau unsupervised clustering of RNA-seq data of the M^+^ST14^hi^ and M^+^ST14^lo^ populations (n = 4 independent experiments for each population).(B and C) RNA expression levels of selected individual genes. The y axis indicates RPKM (reads per kilobase per million). N.S., not significant. (B) Prototypical cholangiocyte marker expression levels were comparable in the duct populations. (C) *Pkhd1l1*, *Bmp4*, *Vim*, and *Rspo1* are examples of differentially expressed genes.(D--F) Representation of differentially expressed gene set enrichment analysis categories. (D) Downregulated cell-cycle checkpoint genes. (E) Upregulated in stem cells (BOQUEST) ([@bib4]). (F) Upregulated in mammary stem cells ([@bib25]).

Gene ontogeny analysis of the differentially expressed genes showed upregulation of genes related to general stem cell properties, mammary stem cells, and hepatoblast pathways in the ST14^hi^ population. This indicates enrichment for stem/progenitor characteristics ([Figure 3](#fig3){ref-type="fig"} and [Table S3](#mmc1){ref-type="supplementary-material"}). In contrast, the cell-cycle checkpoint gene list was downregulated in the ST14^hi^ population ([Figure 3](#fig3){ref-type="fig"}D), consistent with their superior colony-forming ability and growth. Stem/progenitor cell-associated regulators such as *Wnt2b* (7.25-fold) ([@bib13], [@bib16], [@bib33]), *Igfbp5* (10.87-fold) ([@bib26]), *Bmp4* (5.60-fold) ([@bib17]), and *Gpc3* (4.45-fold) ([@bib19]) were more highly expressed in the ST14^hi^ population ([Table 1](#tbl1){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}B). Interestingly, mesenchymal markers such as *Vim* (3.84-fold), the hepatic stellate cell marker *Desmin* (9.60-fold), and cell surface marker *Cd200* (2.54-fold) were enriched as well ([Table 1](#tbl1){ref-type="table"}). Lgr5^+^ cells have been shown to appear in the liver only after injury ([@bib20]). Consistent with this report, *Lgr5* was not expressed in either population of ST14^hi^ cholangiocytes freshly isolated from normal liver. However, *Lgr5* gene expression was ∼80-fold higher in the cultured ST14^hi^ organoids compared with the same cells in monolayer culture, while ST14^lo^ organoids did not express *Lgr5* ([Figure S1](#mmc1){ref-type="supplementary-material"}H).Table 1Selected Genes Differentially Expressed in ST14^hi^ versus ST14^lo^ CholangiocytesGeneST14^hi^ (RPKM)FC (ST14^hi^/ST14^lo^)p ValueFDRLgals7lectin, galactose binding, soluble 76601.83 × 10^−10^0Sfrp2secreted frizzled-related protein 23.7537.51.15 × 10^−8^0Pkhd1l1oolycystic kidney and hepatic disease 1-like 17.75311.58 × 10^−5^0Lrp2low-density lipoprotein receptor-related protein2.5251.58 × 10^−5^0MrgprfG-protein-coupled receptor MrgF2.5252.51 × 10^−6^0Krt14keratin 141.7517.51.61 × 10^−5^0Cdh11cadherin 116.7513.54.61 × 10^−15^0Igfbp5insulin-like growth factor binding protein 5122.2510.872.83 × 10^−5^0Desdesmin129.68.69 × 10^−6^0Wt1Wilms tumor 16.58.671.17 × 10^−10^0Rspo1R-spondin 113.258.253.61 × 10^−5^0Cd34CD34 antigen16.258.131.47 × 10^−5^0Cd248CD248 antigen, endosialin683.44 × 10^−4^0.01Igfbp6insulin-like growth factor binding protein 677.757.973.58 × 10^−6^0Wnt2bWingless-related MMTV integration site 2b7.257.252.75 × 10^−9^0Ognosteoglycin10.756.141.89 × 10^−4^0Bmp4bone morphogenetic protein 475.62.95 × 10^−7^0Sulf2sulfatase 25.255.252.24 × 10^−6^0Gas1growth arrest specific 1215.251.83 × 10^−5^0Gpc3glypican 3304.458.12 × 10^−5^0Vimvimentin104.753.842.52 × 10^−3^0.056Fgf1fibroblast growth factor 110.253.736.17 × 10^−7^0Onecut1one cut domain, family member 191.251.86.02 × 10^−4^0.02Klra2killer cell lectin-like receptor, subfamily A0−155.74 × 10^−4^0.02Ccl5chemokine (C-C motif) ligand 50.25−116.46 × 10^−3^0.1Pla2g7phospholipase A2, group VII0.25−102.64 × 10^−3^0.06Clec12aC-type lectin domain family 12, member a0.25−74.48 × 10^−3^0.08Itgalintegrin alpha L0.75−51.69 × 10^−3^0.04AF251705Cd300D antigen0.75−4.331.93 × 10^−4^0Folr2folate receptor 2 (fetal)2.25−4.332.12 × 10^−3^0.05Bdkrb1bradykinin receptor, beta 11.25−2.82.14 × 10^−3^0.05Cybbcytochrome b-245, beta polypeptide2.75−2.643.03 × 10^−4^0.01Cd38CD38 antigen5.25−2.03.32 × 10^−3^0.07

Anatomic Location of Clonogenic Bile Ducts {#sec2.6}
------------------------------------------

Having established that adult mouse biliary duct cells have heterogeneous organoid-forming ability, we wished to determine their anatomic location within the liver. The RNA-sequencing (RNA-seq) data were mined for marker genes that could be used to visualize the clonogenic bile ducts by RNA fluorescence in situ hybridization (FISH). One of the genes most differentially expressed was *Pkhd1l1* ([Table 1](#tbl1){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}B), which is highly related to the known liver disease gene *Pkhd1* ([@bib39]). The expression of this gene was 31-fold higher in ST14^hi^ cells than in ST14^lo^ cells. None of the commercially available antibodies to PKHD1L1 we tested produced clear immunofluorescent labeling. Therefore, to find the location of Pkhd1l1 expression within the cholangiocyte compartment, we performed concurrent dual-color in situ hybridization with *Pkhd1l1* and *Sox9* mRNA. Since RNA-seq revealed that *Sox9* was equally expressed in clonogenic and non-clonogenic cholangiocytes, this gene was used as a marker for both duct populations ([Figure 4](#fig4){ref-type="fig"}A). *Sox9* mRNA was found only in cholangiocytes with about seven to eight signals per cell being detected on average ([Figure 4](#fig4){ref-type="fig"}C). In contrast, *Pkhd1l1* was expressed in a subpopulation of duct cells ([Figure 4](#fig4){ref-type="fig"}D). Only ∼28% of *Sox9*^+^ cells were found to express *Pkhd1l1* ([Figure 4](#fig4){ref-type="fig"}B) (\>1 signal/cell), which was consistent with the observed ratio of ST14^hi^ versus ST14^lo^ in MIC1-1C3^+^ cells as measured by flow cytometry (∼1:3, [Figure 1](#fig1){ref-type="fig"}). These data indicate that the clonogenic subpopulation of duct cells is found within normal interlobular portal bile duct structures.Figure 4Clonogenic Cholangiocytes Are Interspersed within Normal Bile Ducts(A) Representative image of *Pkhd1l1* (red) and *Sox9* (green) RNA FISH staining. Scale bar, 10 μm.(B) Venn diagram of the *Pkhd1l1*^+^ cells among all *Sox9*^+^ duct cells.(C) Frequency of *Sox9* RNA signals per duct cell.(D) Frequency of *Pkhd1l1* RNA signals per duct cell; 60% of cells has either no or one hybridization signal, delineating the negative population.n = 88 independent experiments from cells in four different mice. Biliary cells were identified by typical morphology in phase-contrast microscopy.

*In Vivo* Engraftment of Mouse Liver Organoids in FRG/N Mice {#sec2.7}
------------------------------------------------------------

To investigate whether ST14^hi^M^+^ mouse liver organoids could expand and repopulate damaged liver after transplantation, we dissociated organoids into single cells and performed intrasplenic transplantation of 500,000 cells (\>6 passages) per recipient into Fah^−/−^/Rag2^−/−^/Il2rg^−/−^/NOD (FRG/N) mice (n = 8 independent host mice and n = 4 organoid donor mice) as previously described ([@bib1], [@bib8], [@bib20]). Of these, four survived NTBC withdrawal. Ten weeks after the transplantation, liver tissues were harvested and labeled to detect hepatocyte markers FAH and HNF4A. Approximately 20 FAH-positive donor-derived hepatocytes nodules were found in each surviving mouse ([Figures 5](#fig5){ref-type="fig"}A--5D). Since the host liver does not express FAH, this observation confirms that the hepatic organoids described herein can give rise to hepatocytes and indeed represent the same Lgr5^+^ population previously reported by us ([@bib8], [@bib20]).Figure 5*In Vivo* Engraftment of ST14^hi^-Derived Organoids(A and B) Immunofluorescent labeling for FAH and HNF4A from serial sections (DAPI stained nuclei as blue).(C and D) Immunofluorescent (C) and immunohistochemistry (D) staining for FAH (nuclei stained with hematoxylin) in the FRG/N mouse liver. An FAH^+^ donor-derived nodule of healthy hepatocytes is illustrated.Scale bars, 100 μm. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Until recently there was consensus that the adult liver harbors facultative stem cells ([@bib29]) which become activated during certain kinds of liver injury, termed oval cell injuries. These facultative liver/stem progenitor cells were deemed to be bipotential, i.e., to give rise to both cholangiocytes and hepatocytes, and be a cell with ductal phenotype located in the canal of Hering. Upon activation, liver stem cells were thought to produce proliferating duct cells (oval cells) and then differentiate into hepatocytes as they migrated out from the portal triad into the hepatic lobule. This previously well-accepted paradigm has now been challenged by lineage-tracing studies performed by several laboratories ([@bib18]). Consistently, these studies have shown no significant contribution of oval cells (identified as proliferating duct cells) to the hepatocyte lineage *in vivo*, at least using the standard injury models in mice.

Other recent studies, however, have demonstrated the existence of a highly proliferative cell resident in normal adult liver that can grow as an Lgr5^+^ organoid in tissue culture and give rise to hepatocytes upon transplantation, albeit inefficiently. Organoid-forming cells have been found to reside within the ductal compartment ([@bib8], [@bib21]), and exist in both mice ([@bib20]) and humans ([@bib21]). Lineage-tracing studies demonstrated that the organoid-forming cell in adult mouse is derived from a SOX9^+^ precursor ([@bib35]). Although it is currently unresolved whether the SOX9^+^ adult liver progenitor can act as a hepatocyte precursor *in vivo*, these cells can be massively expanded *ex vivo*. Therefore, they could potentially serve as an abundant source of transplantable cells if their terminal differentiation into hepatocytes could be made efficient.

At most, 1 out of 20 biliary duct cells will form a primary LGR5^+^ organoid under normal conditions ([@bib8]). This observation suggested that this population is heterogeneous and contains a subset of more highly clonogenic cells. Our experiments here clearly demonstrate that cholangiocytes in the adult mouse are indeed functionally heterogeneous and can be subdivided into clonogenic and non-clonogenic subsets. Only the organoids from ST14^hi^ cells could be serially passaged. The small primary organoids from ST14^lo^ duct cells stopped growing after two passages. Our data therefore indicate that the vast majority, if not all, of serially expandable hepatic organoids derive from the ST14^hi^ clonogenic population. The ST14^hi^ and ST14^lo^ populations were not only distinct in their organoid-forming ability but also had clear differences in gene expression. Although classic cholangiocyte genes were not differentially expressed, \>10-fold differences were observed in many other transcripts. The genes most highly expressed in the clonogenic subset population are candidates to be novel markers of hepatic progenitors, as they delineate the population that produces *Lgr5*^+^ liver organoids. However, it is still uncertain whether the same cells that produce hepatic organoids in culture represent bona fide stem/progenitor cells *in vivo*. Although clonogenic assays can be useful to isolate progenitors in many systems, we did not perform *in vivo* lineage tracing of the clonogenic cholangiocytes to formally prove that they are injury-induced stem/progenitor cells. Given the list of differentially expressed genes, however, it should be possible in the future to generate Cre-driver lines to specifically trace the fate of these cells *in vivo*. Interestingly, none of the many candidate stem cell genes ([Table 1](#tbl1){ref-type="table"}) has been previously considered as oval cell or progenitor markers.

Although we did not perform *in vivo* lineage tracing, we performed experiments to measure the frequency and clonogenicity of our cholangiocyte subsets during injury. Interestingly, neither the percentages nor organoid-forming abilities of the ST14^hi/lo^ populations changed with injury. This could indicate that both populations regenerate equally *in vivo* despite their different clonogenic properties *in vitro*. Alternatively, the clonogenic subset may produce both ST14^hi^ and low daughters during injury. The second hypothesis is supported by the observation that single ST14^hi^ cholangiocytes can produce both ST14-high and -low offspring in organoids *in vitro*. In contrast, ST14^lo^ cells produce only ST14^lo^ offspring *in vitro*. However, no definite conclusions can be made based on the data presented here, and lineage-tracing studies will be needed to formally evaluate the diverging possibilities.

We used one of the new subset markers, *Pkhd1l1*, to localize the clonogenic cholangiocytes in the adult liver in situ. Using RNA FISH we found that they are part of the interlobular biliary ducts in the portal triad and appear morphologically identical to regular cholangiocytes. Our analysis was conducted in only two dimensions and it was therefore not possible to clearly discern whether the *Pkhd1l1* cells were in the canal of Hering. Future detailed three-dimensional reconstructions should resolve this question.

Our data are consistent with a recent report demonstrating heterogeneity in proliferative capacity among cholangiocytes *in vivo* ([@bib22]). In fact the observed frequency of clonogenic duct cells and their anatomic location within the liver fit our observations well. It can be speculated that the ST14^hi^ population reported here may represent the same cells giving rise to large biliary duct clones by lineage tracing *in vivo*. However, our results also indicate differences from the model proposed by [@bib22]. The consistent differences in gene expression between clonogenic and non-clonogenic cholangiocytes found by us suggest inherent differences between the two populations. This is in contrast to the stochastic activation model of a homogeneous population of cholangiocytes proposed by those authors. Interestingly, the existence of distinct populations differing in growth potential has recently also been suggested for hepatocytes ([@bib14], [@bib37]). It is currently unclear for both cholangiocytes and hepatocytes whether the different populations reflect different developmental lineages or whether niche signals are responsible for the divergent phenotypes.

Interestingly, we also found that organoid-forming cells were highly ischemia resistant and retained their clonogenic properties for at least 24 hr after death even at room temperature. This suggests that cadaveric tissue sources could potentially be used to establish expandable cultures of these cells, even from non-beating heart donors. This property makes liver organoids a potentially attractive source of transplantable allogeneic hepatocytes in the future, but only if their hepatocytic differentiation can be made more efficient than it is today. Indeed, the Fah transplantation studies reported here confirmed that the organoids have only rather limited hepatocytic potential. The number of FAH^+^ hepatocyte nodules per input cell was much lower than is seen with transplantation of mature hepatocytes. The development of more efficient protocols to convert expanded organoids into mature hepatocytes should be a research priority for the future.

Experimental Procedures {#sec4}
=======================

Animals and Liver Cell Preparation {#sec4.1}
----------------------------------

Eight-week-old C57B/L6 male mice were purchased from The Jackson Laboratory. All animal experimentation was conducted in accordance with protocol IS000000788 of the institutional review committee at Oregon Health and Science University. To produce single liver cell suspensions for FACS, we perfused mouse livers with 0.5 mM EGTA (Fisher) followed by collagenase (Worthington Biochemical), as described previously ([@bib7]).

Cell Sorting and Culture {#sec4.2}
------------------------

The isolation of defined non-parenchymal cell subpopulations from adult mouse liver was performed as described previously ([@bib7]) with some modifications. In brief, cells were incubated at 4°C for 30 min with MIC1-1C3 hybridoma supernatant at a dilution of 1:20 and anti-human ST14 (Abcam) at a concentration of 1:100. For co-staining of CD133 and ST14, biotinylated anti-CD133 (eBioscience) was used. After a wash with cold PBS containing 3% fetal bovine serum, cells were labeled with phycoerythrin (PE)-conjugated donkey anti-rat and DL647-counjugated donkey anti-rabbit secondary antibodies (Jackson Immunoresearch) and allophycocyanin (APC)-Cy7-conjugated streptavidin (BD Biosciences). After another wash, the secondary antibody was blocked by a 10-min incubation in DMEM containing 5% rat serum. Cells were then incubated with fluorescein isothiocyanate-conjugated anti-CD26 (BD Biosciences) and PE-Cy7-conjugated anti-CD45 (BD Biosciences), anti-CD11b/Mac1 (BD Biosciences), and anti-CD31 (BD Biosciences) to collectively mark hematopoietic and endothelial cells for exclusion. After a final wash, cells were resuspended in holding buffer containing propidium iodide (1 μg mL^−1^) and then analyzed and sorted with a Cytopeia influx-GS (Becton Dickinson). Flow-cytometry data were analyzed by FlowJo (Treestar). For FACS gating, isotype control stained with secondary anti-rabbit APC and anti-rat PE only were used for negative gates. Sorted populations were mixed with Matrigel (BD Bioscience) and seeded and cultured as described previously ([@bib20]) with minor modifications. Culture medium consisted of Advanced DMEM/F12 (Invitrogen) supplemented with B27 and N2 (Invitrogen), 1.25 μM N-acetylcysteine (Sigma-Aldrich), SB431542, and the following growth factors: 50  ng  mL^−1^ EGF (Peprotech), 10% RSPO1 conditioned medium ([@bib20]), 100  ng  mL^−1^ FGF10 (Peprotech), 10  mM nicotinamide (Sigma-Aldrich), and 50  ng  mL^−1^ HGF (Peprotech), 100  ng  mL^−1^ Noggin, and Wnt3a (R&D Systems). For the single-cell assay, cells were sorted directly into organoid medium containing 5% Matrigel in non-tissue culture-treated 96-well plates at a density of 1 cell/well. On culture day 14, organoids were trypsinized with TrypLE (Gibco) and replated into 50 μL of Matrigel droplets in a 24-well plate for further expansion. All of the antibodies are listed in [Table S4](#mmc1){ref-type="supplementary-material"}.

RNA Sequencing {#sec4.3}
--------------

Cells were directly sorted and added into TRIzol-LS for RNA extraction. Libraries were made with the Illumina TruSeq protocol following the manufacturer\'s protocol. Four samples for each population were processed to assure robust comparisons. The sequence reads were trimmed to 44 bases and aligned to the mouse genome NCBI37/mm9 using Bowtie (an ultrafast memory-efficient short-read aligner) version 0.12.7 ([@bib24]). We used custom scripts to count sequences in exons annotated for RefSeq mouse genes. DESeq2 ([@bib27]) was used to calculate the significance of differentially expressed genes based on these counts. Data were analyzed by gene set enrichment analysis ([@bib30], [@bib34]), and FDRs \<0.25 were considered to be significant. The RNA-seq FASTQ data were submitted to the NCBI GEO.

Liver Repopulation Assay {#sec4.4}
------------------------

The transplantations of ductal cell-derived organoids to Fah-deficient mice were performed as described previously ([@bib7], [@bib20]) with some modifications. Briefly, Fah^−/−/^Rag2^−/−/^Il2rg^−/−^ (FRGN) mice ([@bib1]) were pretreated with a urokinase-type plasminogen activator adenovirus 48 hr before transplantation. Before transplantation, liver organoids were exposed to a hepatocytic differentiation medium as described by [@bib21]. NTBC was withdrawn from recipient animals following transplantation, and weight was monitored daily. Upon reaching 80% of their normal weight, NTBC was readministered until health was restored. After four cycles of NTBC withdrawal, mice were euthanized for immunohistochemical assessment of liver engraftment.

Immunofluorescence {#sec4.5}
------------------

Fresh mouse and human tissues were embedded in OCT compound (Sakura) and sectioned for immunofluorescence. Tissue sections were cut at 7 μm and fixed in acetone for 15 min. After washing in 0.05% PBS-Tween 20, sections were blocked at room temperature for 1 hr with 5% serum corresponding to the host species of the secondary antibody. Primary antibody was applied to tissue sections at 4°C overnight. After washing, tissue sections were stained with secondary antibodies as listed in [Table S1](#mmc1){ref-type="supplementary-material"}. Tissue imaging was observed with Zeiss LSM 700 confocal microscope.

RNA Fluorescence In Situ Hybridization {#sec4.6}
--------------------------------------

Fresh frozen tissue was embedded in OCT compound and sectioned at 10 μm thickness. RNA in situ hybridization was performed using RNAscope (ACDbio) following the manufacturer\'s protocol. *Sox9* and *Pkhd1l1* probes were purchased from ACDbio. Tissues were imaged in a Deltavision CoreDV Widefield Deconvolution microscope. More than 300 individual duct cells from three mice were scored for signal enumeration.

RNA Isolation and qRT-PCR {#sec4.7}
-------------------------

Cells were FACS-sorted directly into TRI Reagent LS (MRC, catalog \#TS120). RNA was extracted with isopropanol and immediately treated with DNase I (Thermo Fisher). cDNA was synthesized with the M-MLV reverse transcription kit (Thermo Fisher). Organoids were lysed into TRIzol (Thermo Fisher, \#15596). Relative mRNA expression levels were assessed by qRT-PCR using the LightCycler96 real-time PCR system (Roche). Primer sequences are: mouse *Lgr5* forward 5′-AGT TAT AAC AGC TGG GTT GGC-3′, reverse 5′-GGA AGT CAT CAA GGT TAT TAT AA-3′; mouse *Gapdh* forward 5′-AAG GTC GGT GTG AAC GGA TTT GG-3′, reverse 5′-CGT TGA ATT TGC CGT GAG TGG AG-3′.

Statistical Analyses {#sec4.8}
--------------------

All data are presented as mean ± SD. GraphPad Prism software was used for statistical analyses. p \< 0.05 and p \< 0.01 were considered to be statistically significant and highly significant, respectively.
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Accession Numbers {#app1}
=================

RNA-seq fastq files are available from the NCBI GEO under accession number GEO: [GSE73897](ncbi-geo:GSE73897){#intref0010}.
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